Mirati Therapeutics (NASDAQ:MRTX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Other analysts have also issued research reports about the stock. SunTrust Banks reiterated a “buy” rating and set a $13.00 target price on shares of Mirati Therapeutics in a research note on Monday, October 2nd. CIBC assumed coverage on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $18.00 target price for the company. ValuEngine lowered shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Finally, Cann assumed coverage on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. Mirati Therapeutics currently has a consensus rating of “Buy” and an average target price of $14.75.

Mirati Therapeutics (MRTX) traded down $0.50 during mid-day trading on Tuesday, reaching $24.25. 1,171,008 shares of the company’s stock traded hands, compared to its average volume of 556,570. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $27.85. The company has a market capitalization of $668.09, a price-to-earnings ratio of -7.80 and a beta of 1.61.

Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.16. equities analysts predict that Mirati Therapeutics will post -2.73 EPS for the current year.

In other news, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the stock in a transaction dated Thursday, November 16th. The stock was acquired at an average price of $13.00 per share, for a total transaction of $8,450,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jamie Christensen sold 14,725 shares of the company’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $22.99, for a total transaction of $338,527.75. Following the transaction, the senior vice president now owns 6,395 shares of the company’s stock, valued at approximately $147,021.05. The disclosure for this sale can be found here. Insiders have sold 32,499 shares of company stock valued at $628,464 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP grew its position in shares of Mirati Therapeutics by 46.5% during the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 16,030 shares during the last quarter. PDT Partners LLC bought a new position in shares of Mirati Therapeutics during the second quarter worth about $200,000. Citadel Advisors LLC bought a new position in shares of Mirati Therapeutics during the third quarter worth about $268,000. Goldman Sachs Group Inc. grew its position in shares of Mirati Therapeutics by 845.4% during the second quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after acquiring an additional 87,858 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new position in shares of Mirati Therapeutics during the third quarter worth about $365,000. Institutional investors and hedge funds own 64.68% of the company’s stock.

WARNING: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2018/01/17/mirati-therapeutics-mrtx-upgraded-at-bidaskclub.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.